Get started
Author

Tobias Engler

Observed names: Engler T, Engler, Tobias, T Engler, T. Engler
ORCID: 0000-0002-8063-2053
Observed ORCID: 0000-0002-8063-2053
OpenAlex ID: A5059250883
HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy
2021 · Ana Marcu, Leon Bichmann, et al. · Journal for ImmunoTherapy of Cancer · 247
PDF
The immunopeptidomic landscape of ovarian carcinomas
2017 · Heiko Schuster, Janet K. Peper, et al. · Proceedings of the National Academy of Sciences · 190
PDF
Detection of circulating cell-free HPV DNA of 13 HPV types for patients with cervical cancer as potential biomarker to monitor therapy response and to detect relapse
2023 · Suzana Mittelstadt, Olga Kelemen, et al. · British Journal of Cancer · 43
PDF
Ovarian cyst removal influences ovarian reserve dependent on histology, size and type of operation
2018 · Melanie Henes, Tobias Engler, et al. · Women s Health · 41
PDF
The Clinical Relevance of the NATALEE Study: Application of the NATALEE Criteria to a Real-World Cohort from Two Large German Breast Cancer Centers
2023 · Henning Schäffler, Franziska Mergel, et al. · International Journal of Molecular Sciences · 36
PDF
Feasibility of Adjuvant Treatment with Abemaciclib—Real-World Data from a Large German Breast Center
2022 · Dominik Dannehl, Lea L. Volmer, et al. · Journal of Personalized Medicine · 36
PDF
The HLA Ligand Atlas - A resource of natural HLA ligands presented on benign tissues
2019 · Ana Marcu, Leon Bichmann, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 34
PDF
The efficacy of sacituzumab govitecan and trastuzumab deruxtecan on stable and active brain metastases in metastatic breast cancer patients—a multicenter real-world analysis
2024 · D. Dannehl, D. Jakob, et al. · ESMO Open · 31
Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients – Data from the Real-World Registry PRAEGNANT
2022 · Tobias Engler, Peter A. Fasching, et al. · Geburtshilfe und Frauenheilkunde · 30
A Modern Approach to Endometrial Carcinoma: Will Molecular Classification Improve Precision Medicine in the Future?
2020 · Simone Marnitz, Till Walter, et al. · Cancers · 28
PDF
Platelet-expressed immune checkpoint regulator GITRL in breast cancer
2021 · Yanjun Zhou, Jonas S. Heitmann, et al. · Cancer Immunology Immunotherapy · 24
PDF
Heart rate variability during treatment of breakthrough pain in patients with advanced cancer: a pilot study
2016 · Eva Masel, Patrick Huber, et al. · Journal of Pain Research · 20
PDF
Implementation of an Electronic Patient-Reported Outcome App for Health-Related Quality of Life in Breast Cancer Patients: Evaluation and Acceptability Analysis in a Two-Center Prospective Trial
2021 · Joachim Graf, Nina Sickenberger, et al. · Journal of Medical Internet Research · 19
PDF
Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system
2023 · Mirjam Renovanz, Sylvia C Kurz, et al. · Neuro-Oncology Advances · 18
PDF
Advancing Cancer Therapy Predictions with Patient-Derived Organoid Models of Metastatic Breast Cancer
2023 · Cansu E. Önder, Teresa J. Ziegler, et al. · Cancers · 16
PDF
43O Durvalumab (D) + carboplatin/paclitaxel (CP) + bevacizumab (B) followed by D, B + olaparib (O) maintenance (mtx) for newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm): Updated results from DUO-O
2024 · F. Trillsch, A. Okamoto, et al. · ESMO Open · 15
PDF
Which Patients Do We Need to Test for BRCA1/2 Mutation? Feasibility of Adjuvant Olaparib Treatment in Early Breast Cancer–Real-World Data from Two Large German Breast Centers
2023 · Dominik Dannehl, Tobias Engler, et al. · Cancers · 15
PDF
Neoadjuvant Chemotherapy of Patients with Early Breast Cancer Is Associated with Increased Detection of Disseminated Tumor Cells in the Bone Marrow
2022 · Léa Volmer, André Koch, et al. · Cancers · 15
PDF
Machine learning and patient-reported outcomes for longitudinal monitoring of disease progression in metastatic breast cancer: a multicenter, retrospective analysis
2023 · Thomas M. Deutsch, André Pfob, et al. · European Journal of Cancer · 14
Measuring the Time to Deterioration for Health-Related Quality of Life in Patients With Metastatic Breast Cancer Using a Web-Based Monitoring Application: Longitudinal Cohort Study
2021 · Katharina Brusniak, Manuel Feisst, et al. · JMIR Cancer · 13
PDF
Soluble NKG2DLs Are Elevated in Breast Cancer Patients and Associate with Disease Outcome
2024 · Anna Seller, Christian M. Tegeler, et al. · International Journal of Molecular Sciences · 12
PDF
350MO Omission of chemotherapy and addition of the CDK4/6 inhibitor ribociclib in HER2-positive and hormone-receptor positive metastatic breast cancer – Second interim efficacy analysis of the randomized phase III DETECT V trial
2024 · W. Janni, T.N. Fehm, et al. · Annals of Oncology · 11
PDF
Targeting NKG2DL with Bispecific NKG2D–CD16 and NKG2D–CD3 Fusion Proteins on Triple–Negative Breast Cancer
2023 · Polina Kaidun, Samuel J. Holzmayer, et al. · International Journal of Molecular Sciences · 11
PDF
Tumor-Free Resection Margin Distance in the Surgical Treatment of Node-Negative Squamous Cell Cancer of the Vulva Has No Impact on Survival: Analysis of a Large Patient Cohort in a Tertiary Care Center
2023 · Florin Andrei Taran, Jana Pasternak, et al. · Cancers · 11
PDF
Characterization and clinical management of abnormal cytology findings in pregnant women: a retrospective analysis
2022 · Rosa Freudenreich, Martin Weiss, et al. · Archives of Gynecology and Obstetrics · 11
PDF
Works count: 117
Citation count: 1,054
H-index: 15
I10-index: 28
Year
Topic
Type